dual agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持，单次测定不足以判定批次的稳定性。实验室之间方法转移时，色谱柱品牌与梯度差异常导致保留时间漂移，因此方法验证十分必要。
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
=== Molecular Separations === The well-defined pore structure of organic cages enables selective molecular separations. Molecular cages can discriminate between molecules based on size, shape, and chemical affinity. Gas separation represents a major application, where cages are incorporated into mixed-matrix membranes for selective gas transport. Studies have demonstrated effective separation of CO2/N2, CO2/CH4, and other industrially relevant gas mixtures. The uniform pore size and chemical environment ensure consistent separation performance. In liquid-phase separations, organic cages show promise for challenging molecular separations. Their solution processability enables incorporation into chromatographic stationary phases. The intrinsic chirality of some cage structures allows for enantioselective separations of racemic mixtures, achieving high separation factors for pharmaceutical and fine chemical applications.
Southern African Association of Freight Forwarders (SAAFF) Chartered Institute of Logistics and Transport (CILT) International Federation of Freight Forwarders Associations (IFFFA) The Fuels Industry Association of South Africa (FIASA) Road Freight Association (RFA) SAPICS South African Express Parcel Association (SAEPA) South African Association of Ship Operators and Agents (SAASOA) African Rail Industry Association (ARIA) Commercial Aviation Association of Southern Africa (CAASA) Fresh Produce Exporters' Forum (FPEF)
"Colombia". Human Rights Watch. Archived from the original on February 23, 2006. Retrieved February 24, 2006. "Information about the combatants". Center for International Policy. Retrieved February 24, 2006. "Solutions to Escape the Conflict's Impasse". National Human Development Report 2003. Archived from the original on August 3, 2004. Retrieved February 23, 2006. Extensive ideas on solutions to the Colombia conflict "Colombia 2005 Report". UN High Commissioner for Human Rights. Archived from the original on August 1, 2020. Retrieved February 24, 2006. (Spanish and English) "The Day after Tomorrow: Colombia's FARC and the End of the Conflict" (PDF). International Crisis Group. Archived from the original (PDF) on December 13, 2014. Retrieved December 11, 2014. (Spanish and English) "Squaring Colombia's Circle: The Objectives of Punishment and the Pursuit of Peace". International Center for Transitional Justice. June 2, 2015. Retrieved August 24, 2016. "From Principles to Practice: Challenges of Implementing Reparations for Massive Violations in Colombia". International Center for Transitional Justice. October 19, 2015. Retrieved August 24, 2016. "Political Crime, Amnesties and Pardons: Scope and Challenges". International Center for Transitional Justice. June 2, 2016. Retrieved August 24, 2016. News
=== Encounters with humans === Attacks on humans are rare, but Komodo dragons have been responsible for several human fatalities, both in the wild and in captivity. According to data from Komodo National Park spanning a 38-year period between 1974 and 2012, there were 24 reported attacks on humans, five of them fatal. Most of the victims were local villagers living around the national park. Komodo dragons generally avoid encounters with humans. Juveniles are very shy and will flee quickly into a hideout if a human comes closer than about 100 metres (330 ft). Older animals will also retreat from humans from a shorter distance away. If cornered, they may react aggressively by gaping their mouth, hissing, and swinging their tail. If they are disturbed further, they may attack and bite. Although there are anecdotes of unprovoked Komodo dragons attacking or preying on humans, most of these reports are either not reputable or have subsequently been interpreted as defensive bites. Only very few cases are truly the result of unprovoked attacks by atypical individuals who lost their fear of humans.
=== RMI Training === Remote Medical International provides remote medicine training courses taught by professionally trained and clinically active practitioners. RMI has trained over 13,000 students through public and private training courses including Wilderness First Aid, Wilderness First Responder, Remote Emergency Medical Technician, Remote Medicine for the Advanced Provider, and multiple recertification courses. RMI students include: all branches of the US military, energy companies, US intelligence agencies, law enforcement, FBI, executive protection, border patrol, special operations, national research organizations, National Park and Forest Services, universities, science foundations, guiding services, and individual adventurers.
Sources: en.wikipedia.org
Low rate of homologous RNA recombination in paramyxoviruses probably results from this unusual genomic requirement for polyhexameric length (6n+0). Natural high genomic stability of SeV is a positive feature for it potential use as a vaccine vector or as an oncolytic agent. For any clinical or industrial applications, it is important that SeV genomic and inserted foreign genes would be expressed in a stable way. Due to SeV genetic stability, multiple serial passages of the virus construct in cell cultures or embryonated chicken eggs without drastic genomic changes are possible. SeV constructs are known to stably express a wide variety of heterologous antigens.
Birch wood is fine-grained and pale in colour, often with an attractive satin-like sheen. Ripple figuring may occur, increasing the value of the timber for veneer and furniture-making. The highly decorative Masur (or Karelian) birch, from Betula verrucosa var. carelica, has ripple textures combined with attractive dark streaks and lines. Birch plywood is made from laminations of birch veneer. It is light but strong, and has many other good properties. It is among the strongest and dimensionally most stable plywoods, although it is unsuitable for exterior use. Birch plywood is used to make longboards (skateboard), giving it a strong yet flexible ride. It is also used (often in very thin grades with many laminations) for making model aircraft. Birch wood is often used in the manufacture of popsicle sticks due to its durability, smoothness and neutral flavour. Extracts of birch are used for flavoring and leather oil, and in cosmetics such as soap and shampoo. In the past, commercial oil of wintergreen (methyl salicylate) was made from the sweet birch (Betula lenta). Birch-tar or Russian oil extracted from birch bark is thermoplastic and waterproof; it was used as a glue on, for example, arrows, and also for medicinal purposes. Fragrant twigs of silver and downy birches are used in saunas. Birch is also associated with the feast of Pentecost in Central and Eastern Europe and Siberia, where its branches are used as decoration for churches and homes on this day.
== History == The concept of fatty acid (acide gras) was introduced in 1813 by Michel Eugène Chevreul, though he initially used some variant terms: graisse acide and acide huileux ("acid fat" and "oily acid").
CO2 + NH3 + H2O → (NH4)HCO3 Since ammonium bicarbonate is thermally unstable, the reaction solution is kept cold, which allows the precipitation of the product as white solid. About 100,000 tons were produced in this way in 1997. Ammonia gas passed into a strong aqueous solution of the sesquicarbonate (a 2:1:1 mixture of (NH4)HCO3, (NH4)2CO3, and H2O) converts it into normal ammonium carbonate ((NH4)2CO3), which can be obtained in the crystalline condition from a solution prepared at about 30 °C. This compound on exposure to air gives off ammonia and reverts to ammonium bicarbonate.
Related peer-reviewed clinical research documented the successful short-term implantation of a remotely programmable insulin delivery system in humans, reflecting the collaboration between Sandia engineers and University of New Mexico clinicians. These efforts represent an important component of the early development of implantable insulin delivery systems, highlighting the role of U.S. national laboratories in advancing biomedical device technology alongside academic and commercial research.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.